TY  - JOUR
AU  - Herz, Andreas
AU  - Guberina, Maja
AU  - Pöttgen, Christoph
AU  - Gauler, Thomas
AU  - Ton, That Truong Mike
AU  - Fischedick, Gerrit
AU  - Kiwitt, Lars Oliver
AU  - Lübcke, Wolfgang
AU  - Hoffmann, Christian
AU  - Schuler, Martin
AU  - Metzenmacher, Martin
AU  - Schaarschmidt, Benedikt M
AU  - Bos, Denise
AU  - Opitz, Marcel
AU  - Hautzel, Hubertus
AU  - Darwiche, Kaid
AU  - Bölükbas, Servet
AU  - Grapatsas, Konstantinos
AU  - Jendrossek, Verena
AU  - Gockeln, Lena
AU  - Wirsdörfer, Florian
AU  - Hetzel, Mario
AU  - Mladenov, Emil
AU  - Stuschke, Martin
AU  - Guberina, Nika
TI  - The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis.
JO  - Translational Lung Cancer Research
VL  - 14
IS  - 6
SN  - 2218-6751
CY  - [Erscheinungsort nicht ermittelbar]
PB  - [Verlag nicht ermittelbar]
M1  - DKFZ-2025-01434
SP  - 2074 - 2088
PY  - 2025
AB  - Consolidation therapy with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab, or other immune checkpoint inhibitors, has been associated with improved progression-free and overall survival in patients with stage III non-small cell lung cancer (NSCLC) as demonstrated in randomized clinical trials. The purpose of the present study is to evaluate the dose-response relationship for partial lung infiltrate volumes per dose bin after definitive radiochemotherapy as a sensitive end point to detect a durvalumab effect on the lung parenchyma in patients with subclinical or grade ≤2 pneumonitis.Consecutive patients from a prospective registry with inoperable NSCLC stage III who developed no or pneumonitis grade ≤2 after definitive radiochemotherapy with or without durvalumab consolidation were included. Pulmonary infiltrates outside the planning target volumes were contoured in the follow-up computed tomography (CT) at the time of maximum infiltrate expression. Partial lung infiltrate volumes per dose bin were determined over the entire dose range. A mixed random and fixed effect model was used to fit dose response curves stepwise in dose bins of 5 Gy. The Akaike information criterion (AIC) was used for model comparison.Sixty patients with and 44 without durvalumab consolidation were analysed. The step model showed a significant dose response relationship for the pulmonary infiltrates (P<0.001, F-test) that was modified by the durvalumab effect (P<0.001, F-test). There was a significant dependence of the durvalumab effect on radiation dose (P=0.003). The durvalumab effect increased with dose from 0
KW  - Pneumonitis (Other)
KW  - durvalumab consolidation (Other)
KW  - immunotherapy (Other)
KW  - lung cancer (Other)
KW  - radiation therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40673077
C2  - pmc:PMC12261351
DO  - DOI:10.21037/tlcr-2024-1284
UR  - https://inrepo02.dkfz.de/record/302987
ER  -